Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Antioxidants and Redox Signaling

• Publication date

  2014-02-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/ars.2013.5531PMID 23924053PMCID PMC4692132
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How to balance cardiometabolic benefits and risks of statins.

  2013cited by this paper
• How to balance cardiorenometabolic benefits and risks of statins.

  2013cited by this paper
• How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.

  2013cited by this paper
• Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.

  2013cited by this paper
• An analysis of electronic medical records to evaluate possible bias due to differential survival

  2013cited by this paper
• Statins and Risk of Diabetes

  2013cited by this paper
• Risk of incident diabetes among patients treated with statins: population based study

  2013cited by this paper
• Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes

  2013cited by this paper
• How to Balance Cardiometabolic Benefits and Risks of Statins

  2013cited by this paper
• Reply: To PMID 23219296.

  2013cited by this paper
• Anti-Inflammatory Effects of Statins Beyond Cholesterol Lowering

  2012cited by this paper
• Statins: is it really time to reassess benefits and risks?

  2012cited by this paper
• Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

  2012cited by this paper
• Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.

  2012cited by this paper
• Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E-/- Mice

  2012cited by this paper
• Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study.

  2012cited by this paper
• Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.

  2012cited by this paper
• Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.

  2012cited by this paper
• Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy.

  2012cited by this paper
• Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

  2012cited by this paper
• Caveats to aggressive lowering of lipids by specific statins.

  2012cited by this paper
• 922 SIGNIFICANT DIFFERENTIAL METABOLIC EFFECTS OF ROSUVASTATIN AND PRAVASTATIN IN HYPERCHOLESTEROLEMIC PATIENTS

  2012influential reference
• Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• Tetrahydrobiopterin deficiency and Nitric Oxide Synthase uncoupling contribute to atherosclerosis induced by disturbed flow

  2011cited by this paper
• Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance

  2011cited by this paper
• Prevention of Atherosclerosis in Overweight/Obese Patients

  2011cited by this paper
• Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.

  2011cited by this paper
• Effects of insulin on the vasculature.

  2011cited by this paper
• Diabetes mellitus, fasting glucose, and risk of cause-specific death.

  2011cited by this paper
• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

  2011cited by this paper
• Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin‐induced diabetic mice

  2011cited by this paper
• Differential metabolic effects of distinct statins.

  2011influential reference
• Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive patients

  2011cited by this paper
• Prevention of atherosclerosis in overweight/obese patients. - In need of novel multi-targeted approaches-.

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2010cited by this paper
• Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol.

  2010cited by this paper
• Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.

  2010cited by this paper
• Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

  2010cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• Preoperative Atorvastatin Treatment in CABG Patients Rapidly Improves Vein Graft Redox State by Inhibition of Rac1 and NADPH-Oxidase Activity

  2010cited by this paper
• Hyperglycemia induces inducible nitric oxide synthase gene expression and consequent nitrosative stress via c-Jun N-terminal kinase activation.

  2010cited by this paper
• Modulation of human T cells signaling transduction by lovastatin.

  2010cited by this paper
• Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

  2010cited by this paper
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Effects of Combined Treatment with Angiotensin II Type 1 Receptor Blocker and Statin on Stent Restenosis

  2009cited by this paper
• Major lipids, apolipoproteins, and risk of vascular disease.

  2009cited by this paper
• Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients.

  2009cited by this paper
• Targeting converging therapeutic pathways to overcome hypertension.

  2009cited by this paper
• Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.

  2008cited by this paper
• Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.

  2008cited by this paper
• Does reversal of oxidative stress and inflammation provide vascular protection?

  2008cited by this paper
• Dimethylarginine Dimethylaminohydrolase Overexpression Enhances Insulin Sensitivity

  2008cited by this paper
• Long-term follow-up of the West of Scotland Coronary Prevention Study.

  2008cited by this paper
• The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials

  2008influential reference
• A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance

  2008cited by this paper
• Comparison of the Effect of Lipophilic and Hydrophilic Statins on Serum Adiponectin Levels in Patients with Mild Hypertension and Dyslipidemia: Kinki Adiponectin Interventional (KAI) Study

  2008cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

  2008cited by this paper
• Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

  2008cited by this paper
• NADPH Oxidase Contributes to Vascular Inflammation, Insulin Resistance, and Remodeling in the Transgenic (mRen2) Rat

  2007cited by this paper
• Critical Role for FoxO3a-Dependent Regulation of p21CIP1/WAF1 in Response to Statin Signaling in Cardiac Myocytes

  2007cited by this paper
• Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction

  2007cited by this paper
• Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI.

  2007cited by this paper
• Long-term follow-up of the West of Scotland Coronary Prevention Study.

  2007cited by this paper
• Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms

  2006influential reference
• Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases

  2006cited by this paper
• Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.

  2006cited by this paper
• Treatment of Spontaneously Hypertensive Rats With Rosiglitazone and/or Enalapril Restores Balance Between Vasodilator and Vasoconstrictor Actions of Insulin With Simultaneous Improvement in Hypertension and Insulin Resistance

  2006cited by this paper
• Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.

  2005cited by this paper
• C-reactive protein levels and outcomes after statin therapy.

  2005influential reference
• The union of vascular and metabolic actions of insulin in sickness and in health.

  2005influential reference
• Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.

  2005cited by this paper
• Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes

  2005cited by this paper
• Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients

  2005cited by this paper
• Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.

  2005cited by this paper
• Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia

  2005cited by this paper
• Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients

  2004cited by this paper
• Antioxidant effects of statins.

  2004cited by this paper
• Vascular effects of diet and statin in hypercholesterolemic patients.

  2004cited by this paper
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial Cells

  2003cited by this paper
• Interrelationship of free oxygen radicals and endothelial dysfunction--modulation by statins.

  2003cited by this paper
• Hypercholesterolemia and Hypertension Have Synergistic Deleterious Effects on Coronary Endothelial Function

  2003cited by this paper
• A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms

  2003influential reference
• Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.

  2003cited by this paper
• Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium

  2003cited by this paper
• Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease.

  2003cited by this paper
• Pharmacologic characteristics of statins

  2003cited by this paper
• Low-Level Endotoxin Induces Potent Inflammatory Activation of Human Blood Vessels: Inhibition by Statins

  2003cited by this paper
• HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells

  2003cited by this paper
• Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells

  2002cited by this paper
• Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.

  2002cited by this paper
• Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies.

  2002influential reference
• Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients

  2002cited by this paper
• Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo

  2002cited by this paper
• Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women

  2002cited by this paper

• Statin-Mediated Modulation of Nrf2 Signaling: Mechanisms and Therapeutic Implications in Atherosclerosis.

  2026cites this paper
• Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study

  2025cites this paper
• Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis

  2021cites this paper
• Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study.

  2019cites this paper
• Influence of simvastatin on hepatocytes - histopathological and immunohistochemical study.

  2019cites this paper
• Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis.

  2019cites this paper
• Simvastatin Treatment Protects Myocardium in Noncoronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting

  2018cites this paper
• Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits.

  2018cites this paper
• Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events

  2017cites this paper
• A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT).

  2017cites this paper
• Reply to comment on: Effects of ezetimibe/simvastatin combination on metabolic parameters by Prof. Moses S Elisaf.

  2016cites this paper
• Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients.

  2016cites this paper
• Potential of novel drug delivery strategies for the treatment of hyperlipidemia

  2016cites this paper
• Calming down chaos regarding redefining blood pressure targets-the importance of statin-based therapy.

  2016cites this paper
• 15. Anthelmintic drug discovery: Into the future

  2016cites this paper
• Anthelmintic Drug Discovery: Into the Future

  2015cites this paper
• Modulation of adiponectin as a potential therapeutic strategy.

  2014cites this paper
• Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease.

  2014cites this paper
• Gaining biological perspectives from schistosome genomes.

  2014cites this paper
• Antioxidant effects of statins in the management of cardiometabolic disorders.

  2014cites this paper
• Statins: Pleiotropic Regulators of Cardiovascular Redox State

  2014cites this paper
• How to balance cardiorenometabolic benefits and risks of statins.

  2013cites this paper